InvestorsHub Logo
icon url

scottsmith

08/20/18 5:05 PM

#237885 RE: groton68 #237883

I’m a fact centered, detail oriented person. So these ‘minor’ differences matter to me. Unfortunately for ipix, absssi is also many years away. No one is interested in it. How do I know? Moth balled for over 3 years and counting.
icon url

loanranger

08/20/18 7:28 PM

#237905 RE: groton68 #237883

Which one of these is "the MRSA treatment"?
https://clinicaltrials.gov/ct2/results?cond=&term=galera&cntry=&state=&city=&dist=
Do they have a MRSA treatment?

They HAVE completed a number of Phase 1's and those candidates probably ARE years away, but I think the issue was OM for which they SAY they are "poised to enter phase 3 this year".
I guess that's the same as “The expedient advancement of Brilacidin-OM into later clinical development is a priority, as is the broader expansion of the complete Brilacidin Franchise.” You decide.

Their OM is infused versus oral and I can't compare the numbers for the two, but this doesn't seem to have been a fully considered reaction:
"Galera deal is pre-phase 1. Many years away"

In raising the MRSA issue you obviously also raise the issue of missed opportunities. I hope the analogy isn't the same for OM.